# Discriminator report

## Scenario echo
The scenario is human pancreas with no specified age, sex, disease, treatment, or cell-type restriction, and no notes. The embedding therefore should cover the expected healthy human pancreatic landscape: endocrine islet cells, exocrine acinar and ductal epithelium, vascular and lymphatic endothelium, mesenchymal/perivascular stroma, resident immune populations, and neural/glial elements.

## Rating: minor
The blueprint has a biologically plausible high-level structure and covers the major pancreatic compartments. It needs targeted refinement, mainly in the immune branch and a few marker modules, before I would defend it unchanged for a broad human pancreas embedding.

## Findings

### Minor issues
- **immune_core, t_nk_cell, b_plasma_cell, immune gated axes** — The immune compartment is under-resolved for a whole-pancreas embedding and the gate is biased toward myeloid/APC/inflammatory expression. Healthy human pancreas atlases commonly resolve macrophage/monocyte, dendritic/APC, T, NK, B, plasma, and mast populations. The current blueprint merges T with NK, merges B with plasma, omits dendritic cells, and uses `immune_core` genes such as `LST1`, `LYZ`, `CD74`, `HLA-DRA`, and `CXCL8`, which will gate myeloid/APC cells much more strongly than T/NK cells.
  *Fix:* Revise `immune_core` to a broader pan-leukocyte module, e.g. centered on `PTPRC`, `CD52`, `LCP1`, `CORO1A`, `CD53`, `SRGN`, `LAPTM5`, with minimal lineage bias. Replace the merged T/NK and B/plasma modules with separate T-cell, NK-cell, B-cell, and plasma-cell modules/axes, and add a dendritic-cell/APC axis with canonical markers such as `FCER1A`, `CD1C`, `CLEC10A`, `LILRA4`, `CLEC9A`, `XCR1`, or an appropriately scoped subset supported by the cited pancreas/atlas resource.

- **lymphatic_endothelial** — The lymphatic module is plausible in direction but not marker-clean enough. It includes `PROX1` and `PDPN`, but omits very canonical lymphatic endothelial genes such as `LYVE1`, `FLT4`, `CCL21`, and `MMRN1`; `NTS`, `NRG3`, and `SEMA3D` are weaker and could confuse the axis, especially because `NRG3` is also used in the neural/ganglial module.
  *Fix:* Strengthen this module with core lymphatic endothelial markers (`PROX1`, `PDPN`, `LYVE1`, `FLT4`, `CCL21`, `MMRN1`, optionally `TFF3`/`RELN` if supported by the cited atlas) and drop or de-emphasize weaker niche markers unless the cited pancreas endothelial resource specifically supports them.

- **stromal_core / fibroblast_matrix / mural_pericyte_smooth_muscle** — The stromal branch captures mesenchymal and perivascular cells, but it does not cleanly distinguish pancreatic fibroblast/stellate biology from vascular mural cells. `stromal_core` mixes fibroblast matrix genes with pericyte markers, and `mural_pericyte_smooth_muscle` combines pericytes and smooth muscle into one axis. This is acceptable as a coarse branch, but broad human pancreas should ideally preserve resident pancreatic stellate/fibroblast versus pericyte/smooth-muscle structure.
  *Fix:* If the cited pancreas atlas supports it, add or refine a pancreatic stellate/fibroblast module with matrix/stellate genes such as `DCN`, `LUM`, `COL1A1`, `COL3A1`, `COL6A3`, `PDGFRA`, `RGS5`, `DES`, or `ACTA2` as appropriate, and keep mural/pericyte/smooth-muscle markers (`RGS5`, `PDGFRB`, `CSPG4`, `MCAM`, `NOTCH3`, `MYH11`, `TAGLN`) as a cleaner perivascular axis. Do not add disease-activated fibrosis programs unless explicitly supported for healthy pancreas.

## Out of scope (FYI, not actionable for the Generator)
- I did not verify DOI/title matches or impact-factor eligibility; that is outside this discriminator pass.
- The endothelial niche split into islet/acinar/arterial/venous/lymphatic is more detailed than many pancreas embeddings, but it is not outside scope if the cited pancreas endothelial resource supports those modules.

## Summary for the next round
Keep the overall compartmental scaffold. Focus the next refinement on making the immune branch biologically cleaner and more complete, improving the lymphatic endothelial markers, and modestly cleaning the stromal/perivascular split without adding disease-state axes.
